JARDIANCE® Post Marketing Surveillance in Korean Patients With Chronic Kidney Disease (CKD)
NCT06287073 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 299
Last updated 2026-01-30
Summary
The primary objective is to monitor the safety profile of JARDIANCE® in Korean patient with chronic kidney disease (CKD) in routine clinical practice.
The secondary objective is to monitor the efficacy of JARDIANCE® by evaluating changes in urine albumin-creatinine ratio (UACR) after 12 and/or 24 weeks of treatment.
Conditions
- Kidney Disease, Chronic
Interventions
- DRUG
-
JARDIANCE®
Sponsors & Collaborators
- lead INDUSTRY
Eligibility
- Min Age
- 19 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2024-03-29
- Primary Completion
- 2025-04-30
- Completion
- 2025-04-30
Countries
- South Korea
Study Locations
More Related Trials
-
Sodium-Glucose Cotransporter-2 Inhibitor for Patients With Acute Cardiorenal Syndrome
NCT07273838 ·Status: RECRUITING ·Phase: PHASE2
-
Short-term Use of Dapagliflozin to Protect Kidney Function in CKD Patients
NCT05225077 ·Status: UNKNOWN ·Phase: PHASE4
-
Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Kidney Function in Advanced Chronic Kidney Disease
NCT06982079 ·Status: RECRUITING ·Phase: PHASE3
-
Empagliflozin on Residual Kidney Function in Incident Peritoneal Dialysis Patients
NCT06483074 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Mechanisms of Dapagliflozin in Promoting Kidney Function and Cardiovascular Health in Kidney Transplant Recipients
NCT06140537 ·Status: RECRUITING ·Phase: PHASE4
-
Evaluating Comparative Effectiveness of Empagliflozin in Type 2 Diabetes Population With and Without Chronic Kidney Disease
NCT05465317 ·Status: COMPLETED
-
A Bioequivalence Study of Two Formulations of 10-mg Empagliflozin Tablets in Healthy Thai Volunteers Under Fasting Conditions
NCT06308679 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
Effect of Empagliflozin on Podocyte Specific Proteins in African American Veterans With NDKD
NCT06110130 ·Status: RECRUITING ·Phase: PHASE4
-
Post-authorisation Safety Study in Patients With Type 2 Diabetes to Assess the Risk of Liver Injury, Kidney Injury, Urinary Tract and Genital Infections, and Diabetic Ketoacidosis in Patients Treated With Empagliflozin, Compared to DPP-4 Inhibitors
NCT02864914 ·Status: COMPLETED
-
Dapagliflozin on Renal Morphology and Renal Perfusion in Patients One Year After Kidney Transplantation
NCT06560801 ·Status: RECRUITING ·Phase: PHASE4
-
A Study of Dapagliflozin in Chinese Adult Patients With Chronic Kidney Disease
NCT06610526 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Effect of Evogliptin on Albuminuria in Patients With Type 2 Diabetes and Renal Insufficiency
NCT03667300 ·Status: COMPLETED ·Phase: PHASE2
-
Acute Effects of SGLT2 Inhibitor on Kidney Allograft Oxygen Tension
NCT06933355 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Dapagliflozin in Non-diabetic Stage IV CKD
NCT04794517 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety Study of Isuzinaxib in Subjects With DKD
NCT06962098 ·Status: RECRUITING ·Phase: PHASE2
-
An Observation Study to Evaluate the Renoprotective Effect of Fimasartan in Patients With DKD and Proteinuria
NCT05086549 ·Status: COMPLETED
-
Renohemodynamic Effects of Combined empagliflOzin and LosARtan
NCT04238702 ·Status: COMPLETED ·Phase: PHASE4
-
A Pragmatic Trial Comparing Empagliflozin and Dapagliflozin Through Cluster Randomization Embedded in the Electronic Health Record
NCT06642272 ·Status: RECRUITING ·Phase: PHASE4
-
A Study to Evaluate the Renal Protective Effect (Urine Albumin-to-Creatinine Ratio (UACR)), Efficacy and Safety of Ipragliflozin in Type 2 Diabetes Mellitus Patients With Albuminuria
NCT03118713 ·Status: TERMINATED ·Phase: PHASE4
-
Dapagliflozin and Renal Surrogate Outcomes in Advanced Chronic Kidney Disease
NCT05196347 ·Status: COMPLETED ·Phase: PHASE3
-
Urinary Biomarker-Based Diagnostic and Monitoring System for Chronic Kidney Disease and Real-World Effectiveness of SGLT2 Inhibitors
NCT07348484 ·Status: NOT_YET_RECRUITING
-
Efficacy of Dapagliflozin in Early Diabetic Nephropathy in Type 1 Diabetes
NCT06532682 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4
-
Treatment of Patients With Diabetic Kidney Disease
NCT06187493 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
Vascular Impact of Dapagliflozin in CKD Patients (DAPAVASC)
NCT04930549 ·Status: COMPLETED ·Phase: PHASE2
-
The Efficacy and Safety of Dapagliflozin in Improving Heart Failure in Dialysis Patients
NCT06365541 ·Status: RECRUITING ·Phase: PHASE4